Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

This publication has 28 references indexed in Scilit:

• Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients
  AIDS, 2007
• Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
  AIDS, 2007
• Epidemiology of antiretroviral drug resistance in drug-naïve persons
  Current Opinion in Infectious Diseases, 2007
• British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2006)
  HIV Medicine, 2006
• Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial
  The Lancet, 2006
• TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments
  Journal of Virology, 2005
• Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized Trial
  JAMA, 2004
• A Randomized Trial of 2 Different 4‐Drug Antiretroviral Regimens versus a 3‐Drug Regimen, in Advanced Human Immunodeficiency Virus Disease
  The Journal of Infectious Diseases, 2003
• A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
  AIDS, 2003
• Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
  New England Journal of Medicine, 1999